Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Amyloidosis Diagnosed in Solid Organ Transplant Recipients.

Sharpley FA, Fontana M, Gilbertson JA, Gillmore JD, Hawkins PN, Mahmood S, Manwani R, Martinez-Naharro A, Quarta C, Rezk TM, Rowczenio D, Sachchithanantham S, Whelan CJ, Wechalekar AD, Lachmann HJ.

Transplantation. 2020 Feb;104(2):415-420. doi: 10.1097/TP.0000000000002813.

PMID:
32004234
2.

Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis.

Cohen OC, Sharpley F, Gillmore JD, Lachmann HJ, Sachchithanantham S, Mahmood S, Fontana M, Whelan CJ, Martinez-Naharro A, Kyriakou C, Rabin N, Popat R, Yong K, Cheesman S, Shah R, Hawkins PN, Wechalekar AD.

Br J Haematol. 2020 Jan 26. doi: 10.1111/bjh.16401. [Epub ahead of print]

PMID:
31984481
3.

Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis.

Chacko L, Martone R, Bandera F, Lane T, Martinez-Naharro A, Boldrini M, Rezk T, Whelan C, Quarta C, Rowczenio D, Gilbertson JA, Wongwarawipat T, Lachmann H, Wechalekar A, Sachchithanantham S, Mahmood S, Marcucci R, Knight D, Hutt D, Moon J, Petrie A, Cappelli F, Guazzi M, Hawkins PN, Gillmore JD, Fontana M.

Eur Heart J. 2020 Jan 17. pii: ehz905. doi: 10.1093/eurheartj/ehz905. [Epub ahead of print]

PMID:
31950987
4.

Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis.

Sharpley FA, De-Silva D, Mahmood S, Sachchithanantham S, Ramsay I, Garcia Mingo A, Worthington S, Hughes D, Mehta A, Kyriakou C, Griffiths PD, Wechalekar AD.

Eur J Haematol. 2020 Mar;104(3):230-235. doi: 10.1111/ejh.13366. Epub 2020 Jan 10.

PMID:
31815313
5.

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.

Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, Lachmann HJ, Quarta C, Fontana M, Gillmore JD, Whelan C, Hawkins PN, Wechalekar AD.

Blood. 2019 Dec 19;134(25):2271-2280. doi: 10.1182/blood.2019000834.

PMID:
31578202
6.

A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom.

Sharpley FA, Petrie A, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Whelan CJ, Fontana M, Martinez-Naharro A, Quarta C, Hawkins PN, Wechalekar AD.

Br J Haematol. 2019 Dec;187(5):642-652. doi: 10.1111/bjh.16143. Epub 2019 Aug 13.

PMID:
31410841
7.

Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria.

Sharpley FA, Fontana M, Martinez-Naharro A, Manwani R, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Whelan CJ, Hawkins PN, Wechalekar AD.

Haematologica. 2019 Aug 8. pii: haematol.2019.217695. doi: 10.3324/haematol.2019.217695. [Epub ahead of print]

8.

Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.

Manwani R, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Yong K, Rabin N, Popat R, Kyriakou C, Worthington S, Sharpley F, Smith M, Shah R, Cheesman S, Hawkins PN, Wechalekar AD.

Br J Haematol. 2019 Dec;187(5):638-641. doi: 10.1111/bjh.16122. Epub 2019 Aug 6.

PMID:
31388995
9.

Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers.

Rezk T, Lachmann HJ, Fontana M, Naharro AM, Sachchithanantham S, Mahmood S, Petrie A, Whelan CJ, Pinney JH, Foard D, Lane T, Youngstein T, Wechalekar AD, Hawkins PN, Gillmore JD.

Br J Haematol. 2019 Aug;186(3):460-470. doi: 10.1111/bjh.15955. Epub 2019 May 24.

PMID:
31124579
10.

Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.

Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, Rowczenio DM, Gilbertson JA, Hutt DF, Rezk T, Strehina SG, Caringal-Galima J, Manwani R, Sharpley FA, Wechalekar AD, Lachmann HJ, Mahmood S, Sachchithanantham S, Drage EPS, Jenner HD, McDonald R, Bertolli O, Calleja A, Hawkins PN, Gillmore JD.

Circulation. 2019 Jul 2;140(1):16-26. doi: 10.1161/CIRCULATIONAHA.118.038169. Epub 2019 May 21. Erratum in: Circulation. 2019 Jul 30;140(5):e185.

PMID:
31109193
11.

A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis.

Sharpley FA, Manwani R, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Whelan CJ, Fontana M, Hawkins PN, Wechalekar AD.

Blood Cancer J. 2019 Feb 4;9(2):16. doi: 10.1038/s41408-019-0180-1. No abstract available.

12.

Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic AL amyloidosis.

Rezk T, Davenport A, Gan JJ, Lachmann HJ, Fontana M, Martinez-Naharro A, Sachchithanantham S, Guillotte C, Mahmood S, Petrie A, Whelan CJ, Pinney JH, Foard D, Lane T, Youngstein T, Wechalekar AD, Hawkins PN, Gillmore JD.

Br J Haematol. 2019 Jun;185(5):977-980. doi: 10.1111/bjh.15675. Epub 2018 Nov 18. No abstract available.

PMID:
30450572
13.

The genomic landscape of plasma cells in systemic light chain amyloidosis.

Boyle EM, Ashby C, Wardell CP, Rowczenio D, Sachchithanantham S, Wang Y, Johnson SK, Bauer MA, Weinhold N, Kaiser MF, Johnson DC, Jones JR, Pawlyn C, Proszek P, Schinke C, Facon T, Dumontet C, Davies FE, Morgan GJ, Walker BA, Wechalekar AD.

Blood. 2018 Dec 27;132(26):2775-2777. doi: 10.1182/blood-2018-08-872226. Epub 2018 Nov 16. No abstract available.

PMID:
30446495
14.

Deferred autologous stem cell transplantation in systemic AL amyloidosis.

Manwani R, Hegenbart U, Mahmood S, Sachchithanantham S, Kyriakou C, Yong K, Popat R, Rabin N, Whelan C, Dittrich T, Kimmich C, Hawkins P, Schönland S, Wechalekar A.

Blood Cancer J. 2018 Nov 5;8(11):101. doi: 10.1038/s41408-018-0137-9.

15.

Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience.

Rowczenio D, Quarta CC, Fontana M, Whelan CJ, Martinez-Naharro A, Trojer H, Baginska A, Ferguson SM, Gilbertson J, Rezk T, Sachchithanantham S, Mahmood S, Manwani R, Sharpley F, Wechalekar AD, Hawkins PN, Gillmore JD, Lachmann HJ.

Hum Mutat. 2019 Jan;40(1):90-96. doi: 10.1002/humu.23669. Epub 2018 Nov 1.

PMID:
30328212
16.

Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis.

Sharpley FA, Manwani R, Mahmood S, Sachchithanantham S, Lachmann H, Gilmore J, Whelan C, Hawkins P, Wechalekar A.

Br J Haematol. 2018 Nov;183(4):557-563. doi: 10.1111/bjh.15541. Epub 2018 Aug 10.

PMID:
30095161
17.

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine.

Manwani R, Sachchithanantham S, Mahmood S, Foard D, Sharpley F, Rezk T, Lane T, Quarta C, Fontana M, Lachmann HJ, Gillmore JD, Whelan C, Hawkins PN, Wechalekar AD.

Blood. 2018 Aug 16;132(7):761-764. doi: 10.1182/blood-2018-04-846493. Epub 2018 Jun 20. No abstract available.

PMID:
29925500
18.

Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis.

Rezk T, Gilbertson JA, Rowczenio D, Bass P, Lachmann HJ, Wechalekar AD, Fontana M, Mahmood S, Sachchithanantham S, Whelan CJ, Wong J, Rendell N, Taylor GW, Hawkins PN, Gillmore JD.

Nephrol Dial Transplant. 2018 Feb 1;33(2):241-247. doi: 10.1093/ndt/gfw375.

PMID:
29401357
19.

Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis.

Manwani R, Foard D, Mahmood S, Sachchithanantham S, Lane T, Quarta C, Youngstein T, Rezk T, Lachmann HJ, Gillmore JD, Fontana M, Whelan C, Hawkins PN, Wechalekar A.

Haematologica. 2018 Apr;103(4):e165-e168. doi: 10.3324/haematol.2017.178095. Epub 2018 Jan 5. No abstract available.

20.

Role of 99m Tc-DPD scintigraphy in imaging extra-cardiac light chain (AL) amyloidosis.

Sachchithanantham S, Hutt DF, Quigley AM, Hawkins P, Wechalekar AD.

Br J Haematol. 2018 Nov;183(3):506-509. doi: 10.1111/bjh.14988. Epub 2017 Oct 30. No abstract available.

PMID:
29082513
21.

Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.

Sachchithanantham S, Berlanga O, Alvi A, Mahmood SA, Lachmann HJ, Gillmore JD, Hawkins PN, Harding S, Wechalekar AD.

Br J Haematol. 2017 Nov;179(4):575-585. doi: 10.1111/bjh.14908. Epub 2017 Oct 8.

PMID:
28990174
22.

Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.

Rezk T, Lachmann HJ, Fontana M, Sachchithanantham S, Mahmood S, Petrie A, Whelan CJ, Pinney JH, Foard D, Lane T, Youngstein T, Wechalekar AD, Bass P, Hawkins PN, Gillmore JD.

Kidney Int. 2017 Dec;92(6):1476-1483. doi: 10.1016/j.kint.2017.05.004. Epub 2017 Jul 18.

PMID:
28729034
23.

Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre.

Lane T, Pinney JH, Gilbertson JA, Hutt DF, Rowczenio DM, Mahmood S, Sachchithanantham S, Fontana M, Youngstein T, Quarta CC, Wechalekar AD, Gillmore JD, Hawkins PN, Lachmann HJ.

Amyloid. 2017 Sep;24(3):162-166. doi: 10.1080/13506129.2017.1342235. Epub 2017 Jul 7.

PMID:
28686088
24.

Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis.

Quarta CC, Gonzalez-Lopez E, Gilbertson JA, Botcher N, Rowczenio D, Petrie A, Rezk T, Youngstein T, Mahmood S, Sachchithanantham S, Lachmann HJ, Fontana M, Whelan CJ, Wechalekar AD, Hawkins PN, Gillmore JD.

Eur Heart J. 2017 Jun 21;38(24):1905-1908. doi: 10.1093/eurheartj/ehx047.

25.

Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis.

Rezk T, Whelan CJ, Lachmann HJ, Fontana M, Sachchithanantham S, Mahmood S, Khan F, Khiani R, Tomson J, Youngstein T, Gillmore JD, Hawkins PN, Wechalekar AD.

Br J Haematol. 2018 Jul;182(1):145-148. doi: 10.1111/bjh.14747. Epub 2017 May 9. No abstract available.

PMID:
28485005
26.

A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year.

Carter JP, Foard D, Rannigan L, Aliaz K, Mahmood S, Sachchithanantham S, Fontana M, Quarta C, Martinez De Azcona Naharro A, Youngstein T, Rezk T, Wechalekar A, Whelan C, Lachmann H, Hawkins P, Gillmore J, Lane T.

Amyloid. 2017 Mar;24(sup1):72-73. doi: 10.1080/13506129.2017.1295944. No abstract available.

PMID:
28434320
27.

CMR-Verified Regression of Cardiac AL Amyloid After Chemotherapy.

Martinez-Naharro A, Abdel-Gadir A, Treibel TA, Zumbo G, Knight DS, Rosmini S, Lane T, Mahmood S, Sachchithanantham S, Whelan CJ, Lachmann HJ, Wechalekar AD, Kellman P, Gillmore JD, Moon JC, Hawkins PN, Fontana M.

JACC Cardiovasc Imaging. 2018 Jan;11(1):152-154. doi: 10.1016/j.jcmg.2017.02.012. Epub 2017 Apr 12. No abstract available.

28.

High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot study.

Mahmood S, Sovani M, Smith P, George L, Quarta CC, Sachchithanantham S, Fontana M, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD.

Sleep Med. 2017 Apr;32:191-197. doi: 10.1016/j.sleep.2016.11.021. Epub 2016 Dec 21.

PMID:
28366333
29.

Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid.

Hutt DF, Fontana M, Burniston M, Quigley AM, Petrie A, Ross JC, Page J, Martinez-Naharro A, Wechalekar AD, Lachmann HJ, Quarta CC, Rezk T, Mahmood S, Sachchithanantham S, Youngstein T, Whelan CJ, Lane T, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD.

Eur Heart J Cardiovasc Imaging. 2017 Dec 1;18(12):1344-1350. doi: 10.1093/ehjci/jew325.

PMID:
28159995
30.

Comparison of Free Light Chain Assays:  Freelite and N Latex in Diagnosis, Monitoring, and Predicting Survival in Light Chain Amyloidosis.

Mahmood S, Wassef NL, Salter SJ, Sachchithanantham S, Lane T, Foard D, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD.

Am J Clin Pathol. 2016 Jul;146(1):78-85. doi: 10.1093/ajcp/aqw079. Epub 2016 Jun 27.

PMID:
27353767
31.

European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.

Sachchithanantham S, Roussel M, Palladini G, Klersy C, Mahmood S, Venner CP, Gibbs S, Gillmore J, Lachmann H, Hawkins PN, Jaccard A, Merlini G, Wechalekar AD.

J Clin Oncol. 2016 Jun 10;34(17):2037-45. doi: 10.1200/JCO.2015.63.3123. Epub 2016 Apr 25.

PMID:
27114592
32.

Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study.

Mahmood S, Bridoux F, Venner CP, Sachchithanantham S, Gilbertson JA, Rowczenio D, Wagner T, Sayed R, Patel K, Fontana M, Whelan CJ, Lachmann HJ, Hawkins PN, Gillmore JD, Wechalekar AD.

Lancet Haematol. 2015 Jun;2(6):e241-50. doi: 10.1016/S2352-3026(15)00068-X. Epub 2015 May 6.

PMID:
26688234
33.

Natural history and outcome of light chain deposition disease.

Sayed RH, Wechalekar AD, Gilbertson JA, Bass P, Mahmood S, Sachchithanantham S, Fontana M, Patel K, Whelan CJ, Lachmann HJ, Hawkins PN, Gillmore JD.

Blood. 2015 Dec 24;126(26):2805-10. doi: 10.1182/blood-2015-07-658872. Epub 2015 Sep 21.

34.

Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.

Sachchithanantham S, Offer M, Venner C, Mahmood SA, Foard D, Rannigan L, Lane T, Gillmore JD, Lachmann HJ, Hawkins PN, Wechalekar AD.

Haematologica. 2015 Nov;100(11):1469-76. doi: 10.3324/haematol.2015.128025. Epub 2015 Aug 20.

35.

A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.

Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, Basset M, Hawkins P, Merlini G, Wechalekar AD.

Blood. 2015 Jul 30;126(5):612-5. doi: 10.1182/blood-2015-01-620302. Epub 2015 May 18.

PMID:
25987656
36.

A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis.

Sayed RH, Rogers D, Khan F, Wechalekar AD, Lachmann HJ, Fontana M, Mahmood S, Sachchithanantham S, Patel K, Hawkins PN, Whelan CJ, Gillmore JD.

Eur Heart J. 2015 May 7;36(18):1098-105. doi: 10.1093/eurheartj/ehu506. Epub 2014 Dec 29.

PMID:
25549725
37.

Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting.

Venner CP, Gillmore JD, Sachchithanantham S, Mahmood S, Lane T, Foard D, Roussel M, Rannigan L, Gibbs SDj, Pinney JH, Whelan CJ, Lachmann HJ, Hawkins PN, Wechalekar AD.

Haematologica. 2014 Dec;99(12):e260-3. doi: 10.3324/haematol.2014.108191. Epub 2014 Sep 5. No abstract available.

38.

A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis.

Venner CP, Gillmore JD, Sachchithanantham S, Mahmood S, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, Whelan CJ, Lachmann HJ, Hawkins PN, Wechalekar AD.

Leukemia. 2014 Dec;28(12):2304-10. doi: 10.1038/leu.2014.218. Epub 2014 Jul 16.

PMID:
25027514
39.

Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.

Mahmood S, Venner CP, Sachchithanantham S, Lane T, Rannigan L, Foard D, Pinney JH, Gibbs SD, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD.

Br J Haematol. 2014 Sep;166(6):842-8. doi: 10.1111/bjh.12973. Epub 2014 Jun 13.

PMID:
24930361
40.

Autologous stem cell transplantation in severe treatment-resistant Crohn's disease: long-term follow-up of UK patients treated on compassionate basis.

Snowden JA, Ansari A, Sachchithanantham S, Jackson G, Thompson N, Lobo A, Sanderson J, Kazmi M.

QJM. 2014 Nov;107(11):871-7. doi: 10.1093/qjmed/hcu095. Epub 2014 May 5.

PMID:
24803477
41.

Imaging in systemic amyloidosis.

Sachchithanantham S, Wechalekar AD.

Br Med Bull. 2013;107:41-56. doi: 10.1093/bmb/ldt021. Epub 2013 Jul 29. Review.

PMID:
23896486
42.

Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis.

Roussel M, Sachchithanantham S, Gibbs SD, Venner CP, Pinney JH, Gillmore JD, Lachmann HJ, Hawkins PN, Wechalekar AD.

Br J Haematol. 2013 Sep;162(6):856-8. doi: 10.1111/bjh.12433. Epub 2013 Jun 18. No abstract available.

PMID:
23773011
43.

Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma.

Moore S, Atwal S, Sachchithanantham S, Streetly M, Khan I, Percy L, Narat S, D'Sa S, Rabin N, Johnston R, Schey S, Yong K.

Eur J Haematol. 2013 May;90(5):420-5. doi: 10.1111/ejh.12070. Epub 2013 Mar 14.

PMID:
23294279

Supplemental Content

Loading ...
Support Center